Top

Published in:

01-12-2014 | Clinical Study

Risk factors for intraocular involvement in patients with primary central nervous system lymphoma

Authors: Bum-Joo Cho, Hyeong Gon Yu

Published in: Journal of Neuro-Oncology | Issue 3/2014

Abstract

To determine the risk factors for intraocular involvement in patients with primary central nervous system lymphoma (PCNSL), a retrospective chart review was performed on 136 patients who were pathologically diagnosed with PCNSL. The patients were investigated for demographics, clinical manifestation, and the profile of immunohistochemical tumor biomarkers, as well as for the presence of intraocular involvement of lymphoma at diagnosis or during follow-up. The mean age of the entire cohort was 58.6 ± 12.4 years, and the mean follow-up period was 31.1 ± 30.8 months. Twenty-nine (21 %) patients had an intraocular involvement, among which 20 (69 %) patients presented with intraocular involvement at diagnosis of PCNSL and 9 (31 %) patients developed intraocular involvement after a mean period of 32.4 ± 33.6 months. Of the patients with intraocular involvement, 8 (28 %) had no visual symptom at the diagnosis of ocular invasion. Between those with and without intraocular involvement, no significant differences were found with respect to the age, sex, and follow-up period as well as cerebrospinal fluid spread and bone marrow involvement. Among the immunohistochemical biomarkers, the Ki-67 proliferation index was significantly higher in patients with intraocular involvement than in patients without (P = 0.021), but the other investigated biomarkers did not show a significant difference between the two groups. A Ki-67 level ≥80 % was a risk factor for the intraocular involvement in patients with PCNSL (odds ratio, 2.63). Median overall survival was 39.0 months in the entire cohort and was not significantly different between those with and without intraocular involvement (P = 0.959).

Welch MR, Omuro A, Deangelis LM (2012) Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. Neuro Oncol 14:1304–1311. doi:10.1093/neuonc/nos207 PubMedCentralPubMedCrossRef

O’Neill BP, Decker PA, Tieu C, Cerhan JR (2013) The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin’s lymphoma. Am J Hematol 88:997–1000. doi:10.1002/ajh.23551 PubMedCrossRef

Yang SH, Lee KS, Kim IS, Hong JT, Sung JH, Son BC, Lee SW, Hong YK (2009) Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy:role of STAT6 activation as prognostic determinant. J Neurooncol 92:65–71. doi:10.1007/s11060-008-9736-9 PubMedCrossRef

Iwadate Y, Suganami A, Ikegami S, Shinozaki N, Matsutani T, Tamura Y, Saeki N, Yamanaka R (2014) Non-deep-seated primary CNS lymphoma: therapeutic responses and a molecular signature. J Neurooncol 117:261–268. doi:10.1007/s11060-014-1379-4 PubMedCrossRef

Chamberlain MC, Johnston SK (2010) High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro Oncol 12:736–744. doi:10.1093/neuonc/noq011 PubMedCentralPubMedCrossRef

Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, Cassoux N, Touitou V, Smith JR, Batchelor TT, Pulido JS (2011) Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist 16:1589–1599. doi:10.1634/theoncologist.2011-0210 PubMedCentralPubMedCrossRef

Mochizuki M, Singh AD (2009) Epidemiology and clinical features of intraocular lymphoma. Ocul Immunol Inflamm 17:69–72. doi:10.1080/09273940902957305 PubMedCrossRef

Grimm SA, McCannel CA, Omuro AM, Ferreri AJ, Blay JY, Neuwelt EA, Siegal T, Batchelor T, Jahnke K, Shenkier TN, Hall AJ, Graus F, Herrlinger U, Schiff D, Raizer J, Rubenstein J, Laperriere N, Thiel E, Doolittle N, Iwamoto FM, Abrey LE (2008) Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology 71:1355–1360. doi:10.1212/01.wnl.0000327672.04729.8c PubMedCentralPubMedCrossRef

Hong JT, Chae JB, Lee JY, Kim JG, Yoon YH (2011) Ocular involvement in patients with primary CNS lymphoma. J Neurooncol 102:139–145. doi:10.1007/s11060-010-0303-9 PubMedCrossRef

10.

Momota H, Narita Y, Maeshima AM, Miyakita Y, Shinomiya A, Maruyama T, Muragaki Y, Shibui S (2010) Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma. J Neurooncol 98:341–348. doi:10.1007/s11060-009-0078-z PubMedCrossRef

11.

Raoux D, Duband S, Forest F, Trombert B, Chambonniere ML, Dumollard JM, Khaddage A, Gentil-Perret A, Peoc’h M (2010) Primary central nervous system lymphoma: immunohistochemical profile and prognostic significance. Neuropathology 30:232–240. doi:10.1111/j.1440-1789.2009.01074.x PubMedCrossRef

12.

Jahnke K, Korfel A, Komm J, Bechrakis NE, Stein H, Thiel E, Coupland SE (2006) Intraocular lymphoma 2000–2005: results of a retrospective multicentre trial. Graefes Arch Clin Exp Ophthalmol 244:663–669. doi:10.1007/s00417-005-0138-9 PubMedCrossRef

13.

DeAngelis LM, DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ, Radiation Therapy Oncology Group S (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20:4643–4648PubMedCrossRef

14.

Bullwinkel J, Baron-Luhr B, Ludemann A, Wohlenberg C, Gerdes J, Scholzen T (2006) Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol 206:624–635. doi:10.1002/jcp.20494 PubMedCrossRef

15.

Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710–1715PubMed

16.

Alexandrakis MG, Passam FH, Kyriakou DS, Dambaki K, Niniraki M, Stathopoulos E (2004) Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma. Am J Clin Oncol 27:8–13PubMedCrossRef

17.

Li R, Heydon K, Hammond ME, Grignon DJ, Roach M 3rd, Wolkov HB, Sandler HM, Shipley WU, Pollack A (2004) Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res 10:4118–4124. doi:10.1158/1078-0432.CCR-1052-03 PubMedCrossRef

18.

Stuart-Harris R, Caldas C, Pinder SE, Pharoah P (2008) Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 17:323–334. doi:10.1016/j.breast.2008.02.002 PubMedCrossRef

19.

Cummings TJ, Provenzale JM, Hunter SB, Friedman AH, Klintworth GK, Bigner SH, McLendon RE (2000) Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis. Acta Neuropathol 99:563–570PubMedCrossRef

20.

Indinnimeo M, Cicchini C, Stazi A, Limiti MR, Ghini C, Mingazzini P, Vecchione A (2000) Immunohistochemical assessment of Ki-67 as prognostic cellular proliferation marker in anal canal carcinoma. J Exp Clin Cancer Res 19:471–475PubMed

21.

Gaudio F, Giordano A, Perrone T, Pastore D, Curci P, Delia M, Napoli A, de Risi C, Spina A, Ricco R, Liso V, Specchia G (2011) High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab. Acta Haematol 126:44–51. doi:10.1159/000324206 PubMedCrossRef

22.

Miller TP, Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, Foucar K, Kjeldsberg CR, Levy N, Nathwani BN et al (1994) Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin’s lymphomas: a prospective Southwest Oncology Group trial. Blood 83:1460–1466PubMed

23.

Lossos IS, Morgensztern D (2006) Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 24:995–1007. doi:10.1200/JCO.2005.02.4786 PubMedCrossRef

24.

Coupland SE, Damato B (2008) Understanding intraocular lymphomas. Clin Exp Ophthalmol 36:564–578. doi:10.1111/j.1442-9071.2008.01843.x CrossRef

25.

McCann KJ, Ashton-Key M, Smith K, Stevenson FK, Ottensmeier CH (2009) Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development. Blood 113:4677–4680. doi:10.1182/blood-2008-09-179366 PubMedCrossRef

26.

Davis JL (2013) Intraocular lymphoma: a clinical perspective. Eye 27:153–162. doi:10.1038/eye.2012.250 PubMedCentralPubMedCrossRef

27.

Seki R, Ohshima K, Fujisaki T, Uike N, Kawano F, Gondo H, Makino S, Eto T, Moriuchi Y, Taguchi F, Kamimura T, Tsuda H, Ogawa R, Shimoda K, Yamashita K, Suzuki K, Suzushima H, Tsukazaki K, Higuchi M, Utsunomiya A, Iwahashi M, Imamura Y, Tamura K, Suzumiya J, Yoshida M, Abe Y, Matsumoto T, Okamura T (2009) Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 100:1842–1847. doi:10.1111/j.1349-7006.2009.01268.x PubMedCrossRef

28.

Shamas-Din A, Kale J, Leber B, Andrews DW (2013) Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb Perspect Biol 5:a008714. doi:10.1101/cshperspect.a008714 PubMedCrossRef

29.

Song MK, Chung JS, Joo YD, Lee SM, Oh SY, Shin DH, Yun EY, Kim SG, Seol YM, Shin HJ, Choi YJ, Cho GJ (2011) Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma. J Neurooncol 104:825–831. doi:10.1007/s11060-011-0555-z PubMedCrossRef

30.

Ponzoni M, Issa S, Batchelor TT, Rubenstein JL (2014) Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma. Ann Oncol 25:316–322. doi:10.1093/annonc/mdt385 PubMedCrossRef

31.

Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, O’Reilly SE, Hoskins P, Coldman AJ, Reed JC, Connors JM (1997) Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood 90:244–251PubMed

32.

Park S, Lee J, Ko YH, Han A, Jun HJ, Lee SC, Hwang IG, Park YH, Ahn JS, Jung CW, Kim K, Ahn YC, Kang WK, Park K, Kim WS (2007) The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 110:972–978. doi:10.1182/blood-2007-01-067769 PubMedCrossRef

33.

Utsuki S, Oka H, Miyajima Y, Kijima C, Yasui Y, Fujii K (2011) Epstein-Barr virus (EBV)-associated primary central nervous system lymphoma: is incidence of EBV expression associated with median survival time? Brain tumor pathology 28:145–149. doi:10.1007/s10014-011-0020-x PubMedCrossRef

34.

Kuze T, Nakamura N, Hashimoto Y, Sasaki Y, Abe M (2000) The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV(+) and EBV(-) cases in Japanese population. Jpn J Cancer Res 91:1233–1240PubMedCrossRef

35.

Jamal SE, Li S, Bajaj R, Wang Z, Kenyon L, Glass J, Pang CS, Bhagavathi S, Peiper SC, Gong JZ (2014) Primary central nervous system Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a clinicopathologic study of five cases. Brain Tumor Pathol. doi:10.1007/s10014-013-0173-x PubMed

36.

Suh YL, Koo H, Kim TS, Chi JG, Park SH, Khang SK, Choe G, Lee MC, Hong EK, Sohn YK, Chae YS, Kim DS, Huh GY, Lee SS, Lee YS (2002) Tumors of the central nervous system in Korea: a multicenter study of 3221 cases. J Neurooncol 56:251–259PubMedCrossRef

37.

Balmaceda C, Gaynor JJ, Sun M, Gluck JT, DeAngelis LM (1995) Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications. Ann Neurol 38:202–209. doi:10.1002/ana.410380212 PubMedCrossRef

Title: Risk factors for intraocular involvement in patients with primary central nervous system lymphoma
Authors: Bum-Joo Cho
Hyeong Gon Yu
Publication date: 01-12-2014
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2014
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-014-1581-4

At a glance: The STEP trials

Springer Medicine

Risk factors for intraocular involvement in patients with primary central nervous system lymphoma

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Risk factors for venous thromboembolism in patients undergoing craniotomy for neoplastic disease

Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients

Incidence of medulloblastoma in Canadian children

Erratum to: Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry

Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution

Erratum to: The survival of patients with high grade glioma from different ethnic groups in South East England